Skin-Saving paste for cancer radiation falls short in tiny trial
NCT ID NCT01408407
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether Alkagin paste could prevent skin damage in patients receiving radiation for anal, rectal, or gynecological cancers. Only 2 people enrolled before the trial was stopped early. Because of this, we cannot draw any reliable conclusions about the paste's effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Alkagin paste
- What this could lead to
- If it worked, this could offer a way to prevent painful skin burns in patients receiving radiation for pelvic cancers.
- What could go wrong
- The trial was terminated early with only 2 participants, so we have very little data. It is unclear if Alkagin paste is effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Could cutting one amino acid make rectal cancer treatment more effective?
- Video analysis could personalize rehab for chemo nerve damage
- New care model aims to close cancer treatment gaps for people with mental illness
- Can a smartphone program help cancer patients decide about fertility?